PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · AJP Rep 2023; 13(04): e78-e81
DOI: 10.1055/s-0043-1777099
Case Report

A Case of Significant Transaminitis with Liver Biopsy in a Pregnant Patient with COVID-19

Dana Senderoff Berger 
1   Department of Obstetrics and Gynecology, University of California, Irvine, Orange, California
,
Anna Galyean
2   Department of Obstetrics and Gynecology, Southern California Permanente Medical Group, Pasadena, California
,
Kelvin Nguyen
3   Department of Gastroenterology, Southern California Permanente Medical Group, Pasadena, California
,
Najeeb Alshak
4   Department of Pathology, Southern California Permanente Medical Group, Pasadena, California
,
Elizabeth Blumenthal
2   Department of Obstetrics and Gynecology, Southern California Permanente Medical Group, Pasadena, California
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 
 als PDF herunterladen Lizenzen und Reprints

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has led to a global health crisis. The virus can cause varying severity of liver injury, but the mechanism has not yet been elucidated, especially in pregnancy.

We present a morbidly obese 30-year-old woman with COVID-19 at 28 weeks' gestation complicated by significant transaminitis with peak liver enzymes levels of 501/1,313 (aspartate aminotransferase/alanine aminotransferase). Liver biopsy showed reactive changes consistent with medication effect and mild steatosis.

Significant transaminitis has been found in both pregnant and nonpregnant patients with COVID-19. Our case demonstrates the multifactorial nature of liver injury in COVID-19 patients including mild underlying liver steatosis combined with possible viral potentiation of medication effect.


 

Keywords

COVID-19 - pregnancy - hepatic manifestations - liver - transaminitis - viral injury - hepatocellular damage

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in December 2019 in Wuhan, China and spread rapidly around the world, becoming a substantial threat to public health globally. Certain vulnerable populations such as the elderly[1] and those with medical comorbidities[2] [3] [4] have been found to be at greater risk of severe disease, and there is speculation that pregnancy may be another vulnerable population.[5] [6] COVID-19 primarily impacts the lungs, causing acute respiratory distress syndrome; however, other organs have been found to be affected as well, including the kidneys,[3] heart,[7] gastrointestinal tract, bile ducts, and liver.[8] [9] The virus has been found to cause liver function abnormalities of varying degrees from mild transaminitis to severe liver injury,[9] [10] but the exact mechanism of liver injury in these cases is unknown. Here, we describe a case of a pregnant woman with COVID-19 who developed significant transaminitis and had a liver biopsy performed.

Case

A 30-year-old gravida 3 para 1101 with diet-controlled gestational diabetes, obesity with body mass index (BMI) 45, fatty liver found on ultrasound 7 years prior, history of laparoscopic cholecystectomy, and a history of preterm delivery had sore throat, cough, and fever and was found to have a positive COVID-19 test 2 days later. Six days after her positive COVID-19 test (285/7 weeks), she presented with worsening cough, new shortness of breath, and persistent fever up to 101.7. She had taken a limited amount of acetaminophen (less than 3 g/24 hours) at home prior to admission. She was admitted to the hospital for observation and supportive care.

On the day of admission, her temperature was 100.2, heart rate 114, and peripheral capillary oxygen saturation (SpO2) 91 to 94% on room air. She was started on supplemental oxygen by nasal cannula (1–3 L per minute throughout her hospitalization). Medications included dexamethasone 6 mg by mouth daily, a therapeutic heparin drip, and a vitamin regimen (melatonin, thiamine, zinc, ascorbic acid) per hospital COVID-19 protocol. Additional medications included prenatal vitamin, famotidine, calcium carbonate, and acetaminophen pro re nata.

Her acetaminophen quantity throughout the hospitalization was 1,000 mg on hospital day (HD) 1, 1,650 mg on HD 2, and 650 mg on two other occasions (HD 6, HD 10). She received her weekly 17-hydroxyprogesterone injection (for history of preterm delivery) on HD 5; however, this was subsequently discontinued.

Throughout her hospitalization she continued to symptomatically improve. While her cough was persistent, hypoxia was mostly isolated to nighttime during sleeping, requiring between 1 and 3 L per minute supplemental oxygen by nasal cannula at night. Fetal monitoring was reassuring.

On HD 5, despite symptom improvement, her liver function tests were noted to have increased, with aspartate aminotransferase (AST) of 172 and alanine aminotransferase (ALT) of 209 ([Table 1]). Notably, baseline liver function tests prior to and at the beginning of pregnancy were within normal limits. She felt well subjectively and denied any symptoms suggestive of preeclampsia. Blood pressure remained normal. She appeared well on physical exam without hyperreflexia or abdominal discomfort.

Table 1

Pertinent laboratory values throughout hospital admission

HD 1

HD 5

HD 6

HD 7

HD 8

HD 9

HD 10

HD 11

HD 12

HD 13

11 days discharge

Total bilirubin, mg/dL

1.6

1.3

1.0

1.1

1.0

1.3

1.2

1.2

0.5

0.9

0.4

Aspartate aminotransferase (AST), U/L

30

172

212

284

441

501

500

415

321

269

47

Alanine aminotransferase (ALT), U/L

30

209

337

524

846

1,115

1,313

1,336

1,093

981

105

Alkaline phosphatase, U/L

100

118

120

117

121

121

124

114

102

100

71

International normalized ratio (INR)

0.9

1.2

1.0

1.1

1.0

1.0

1.0

1.0

Platelets

197

385

396

470

495

529

550

489

365

362

190

Fibrinogen, mg/dL

750

1,043

886

934

912

966

980

8,766

817

821

Ferritin, ng/mL

178

623

683

568

1,036

1,159

979

757

463

366

Lactate dehydrogenase (LDH), IU/L

198

400

342

346

380

433

406

295

257

323

Abbreviation: HD, hospital day.


Other notable negative laboratories included hepatitis A, B, C, and E serologies, Epstein–Barr virus, cytomegalovirus immunoglobulin M (IgM), herpes simplex virus IgM, antimitochondrial and anti-smooth muscle antibodies, antinuclear antibody, and antineutrophil cytoplasmic antibody. She had a negative immunoglobulin panel and ammonia levels within normal limits.

Her urine protein to creatinine ratio was 0.22 with a 24-hour urine protein of 319. Her creatinine, platelets, international normalized ratio, and haptoglobin remained normal.

An abdominal ultrasound suggested hepatomegaly (craniocaudal diameter 21.27 cm). Liver echogenicity was slightly increased, and liver echotexture was coarse. The gallbladder was surgically absent, and the abdominal vasculature was normal.

While her 24-hour urine protein was suggestive of mild proteinuria, the absence of elevate blood pressures or symptoms of preeclampsia made both preeclampsia and acute fatty liver disease of pregnancy unlikely.

On HD 10, a liver biopsy was performed given concern for persistently increasing transaminases, with AST max of 501 and ALT max of 1,313.

The liver biopsy showed reactive changes consistent with medication effect—prescription or over-the-counter supplement—as well as mild steatosis ([Figs. 1] and [2]). Trichrome and reticulin stains were performed. There was no significant fibrosis. Iron stains were negative as was the periodic acid-Schiff with and without diastase stain for α-1 antitrypsin granules.

Zoom
Fig. 1 Hematoxylin-eosin-stained liver biopsy showing portal tract with normal bile duct (arrow) (magnification ×100).
Zoom
Fig. 2 Hematoxylin-eosin-stained liver biopsy showing reactive changes (magnification ×80).

Following the biopsy, her transaminases stabilized and as she had appeared well for several days therefore was discharged home with follow-up. Eleven days following her hospitalization her transaminases had declined and she continued to feel well.


 

Discussion

COVID-19 has become a global health crisis and there remain many unknowns regarding which populations are the most vulnerable and how the virus impacts different organ systems of the body.

Prior pandemics such as that from H1N1 influenza suggest higher morbidity and mortality among affected pregnant women[11]; however, current evidence is mixed regarding the relationship between pregnancy and the severity of COVID-19. Reports from early in the pandemic from China, the epicenter of the outbreak, suggested that pregnant women are not more severely affected by COVID-19.[12] [13] And a study from March to April 2020 in New York City did not find higher rates of intensive care unit admission in pregnant compared with nonpregnant women.[6] However, more recently there have been several case reports demonstrating severe maternal morbidity secondary to COVID-19 in pregnancy,[5] [14] [15] [16] [17] [18] and subsequent studies have suggested that pregnant women may be a more vulnerable population.[19]

While the lung is the primary organ affected by the virus in both pregnant and nonpregnant individuals, other organs including the liver have been found to be impacted as well, especially in more severe cases. Guan et al report incidence of elevated AST levels to be 18.2 and 39.4% of patients with nonsevere and severe disease, respectively, and incidence of elevated ALT levels to be 19.8 and 28.1% of patients with nonsevere and severe disease, respectively.[20] Data from large U.S. studies show elevated ALT is observed in approximately 39% of patients with COVID-19 infection, mostly below 80 U/L.[21] [22] It is not currently known if SARS-CoV-2 causes direct liver injury or if liver injury in the setting of COVID-19 is secondary to other factors. Other proposed mechanisms of secondary liver injury as a result of COVID-19 include simultaneous use of hepatotoxic drugs, systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ failure.[8] Hepatotoxic drugs that may be administered in the setting of COVID-19 include antiviral medications, investigational drugs, or more commonly used medications such as acetaminophen. In our case, the patient had taken limited amount of acetaminophen prior to hospital admission (< 3 g/24 h) and then 1,000 mg on HD 1, 1,650 mg on HD 2, and 650 mg on two other occasions. In addition, she had received her scheduled dose of 17-hydroxyprogesterone.

There have been some reports of liver biopsies among patients with liver injury in the setting of COVID-19. One case report from a patient with severe acute respiratory distress who died from COVID-19 in China reported a liver biopsy showing moderate microvesicular steatosis and mild lobular and portal activity, consistent with either viral injury or drug-induced liver injury.[23] Other cases report liver pathologic findings of mild sinusoidal lymphocytic infiltration and sinusoidal dilatation, with some reports of multifocal hepatic necrosis as well.[10] Our case reports a liver biopsy with reactive changes consistent with medication effect as well as mild steatosis.

Some have suggested that obesity and nonalcoholic fatty liver disease (NAFLD) may be a risk factor in the development of drug-induced hepatotoxicity,[24] including acetaminophen-induced liver injury.[25] The patient presenting in our case had morbid obesity with a BMI of 45 with known radiologic evidence suggesting fatty liver on ultrasound, therefore it is possible that underlying obesity and mild NAFLD may have contributed to the acute liver injury during her COVID-19 course.

There has also been data to suggest that certain viruses such as human immunodeficiency virus and hepatitis C may increase susceptibility for drug-induced liver disease such as secondary to acetaminophen toxicity.[26] [27] [28] It is possible that SARS-CoV-2 has a similar effect of potentiating hepatotoxic drug effects on the liver.

There remain many unknowns both about the effect of COVID-19 on pregnancy and on acute liver injury. In our case, it is likely that the liver injury with an unusual elevation of ALT above 1,000 U/L in the setting of COVID-19 is multifactorial with contribution from the virus itself, and medications with liver metabolism (acetaminophen and 17-hydroxyprogesterone) on a liver potentially already affected by preexisting fatty liver disease. This case also demonstrates the significant transaminitis that can occur in such cases. Further investigation regarding the impact of COVID-19 on the liver as well as the mechanism of action of these effects is warranted.


 

 

Conflict of Interest

None declared.


Address for correspondence

Dana Senderoff Berger, MD
Department of Obstetrics and Gynecology, University of California
101 The City Drive South, Orange, CA 92868

Publikationsverlauf

Eingereicht: 23. November 2020

Angenommen: 30. August 2023

Artikel online veröffentlicht:
28. November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA


  Lizenzen und Reprints
Zoom
Fig. 1 Hematoxylin-eosin-stained liver biopsy showing portal tract with normal bile duct (arrow) (magnification ×100).
Zoom
Fig. 2 Hematoxylin-eosin-stained liver biopsy showing reactive changes (magnification ×80).